Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.

Alector, Inc. Common Stock

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Alector, Inc.

We have always walked our own path, at Alector. That’s what led us to the bold thinking and fresh, new approach of empowering the body’s immune system to fight disease. 

Join us in our mission to eliminate neurodegeneration and cancer through immuno-neurology and immuno-oncology. We are developing a broad portfolio of programs, currently in various stages of clinical trials. 

Alector is based in South San Francisco, CA. We were founded in 2013 by thought leaders in biotechnology, neuroscience, and antibody drug discovery.

INmuneBIO

OrbiMed

Polaris Partners

Mission Bay Capital

Section 32 Mission BioCapital

Casdin Capital

Google Ventures

Deerfield Capital Management

Euclidean Capital

Amgen Ventures

Alector

2023 was an exceptional year for Alector. Patients & their families were at the forefront of our minds as we executed on our mission and moved closer to achieving our ambitious vision of making brain disorders history. Below, Alector leaders Arnon Rosenthal and Sara Kenkare-Mitra share their reflections on this year as we head into #2024.

Last week, Alector hosted two R&D webinars for analysts, investors & industry on our targets TREM2 and PGRN and shared the significant progress we have made across our clinical programs. We were joined by esteemed thought leaders in the field who contributed to an invaluable dialog. You can catch up on the conversation at the link below. 

Alector continues to be a pioneer in immuno-neurology, and we are excited about the potential to make a difference in the lives of people with #neurodegenerative diseases. 

https://lnkd.in/eARBjk6

During this season of gratitude, we're reminded how lucky we are to have the opportunity to #giveback to our local community. We partnered with Family Giving Tree once again this holiday season to collect gifts and funds for local families in need. We're inspired by the incredibly valuable work organizations like these do. 🎁

The holidays offer a unique opportunity to remind loved ones how much we care about them through gifts or quality time. Taking care of our brain health becomes increasingly important as we grow older. Check out Alector’s top 6 evidence-based holiday gift ideas for enhancing cognitive reserve and lowering risk of #dementia.

Sources: https://lnkd.in/es7R7PAD

The commitment to advocating for, and caring for, people living with a #neurodegenerative disease does not stop, regardless of the season. This winter, we continue to be in awe of our advocacy group partners and their dedication to patients and their families. Thank you for all you do.

Metric
Company Name	Alector, Inc. Common Stock
Symbol	ALEC
MSH ID	COM:ALECTOR
Market	STOCKS
Sector	Healthcare
Industry	Biotechnology
Country	US
Stage
Employee Count	241
Website	alector.com
LinkedIn
Founders

Metric
Market Cap	385.85M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	97.06M
Revenue (LTM)
Revenue (NTM)
Gross Profit	88.21M
EBITDA	-142.89M
Operating Income	-151.74M
Net Income	-130.39M
EPS	-1.56
Diluted EPS	-1.56
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score	93.78
28-Day Growth Score	67.79
90-Day Growth Score	14.30
365-Day Growth Score	64.70

Metric
Gross Profit Margin	0.86
Operating Profit Margin	-1.51
EBITDA Margin	-1.47
Net Profit Margin	-1.25
Return on Equity	-0.72
Return on Assets	-0.19
Return on Capital Employed	-0.31

COM:ALECTOR

Alector, Inc.

Last Close

3.76

22/11 21:00

Market Cap

483.85M

Beta: -

Volume Today

715.70K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-3.58
P/B Ratio	3.11
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	10.81
EV Multiple	-2.42

Metric
Days Sales Outstanding	39.66
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle	-104.54
Asset Turnover	0.16

Metric
Operating Cash Flow	-184.16M
Free Cash Flow	-186.54M
Cash Flow to Debt	-4.26
Operating Cash Flow/Sales	-1.90
Free Cash Flow Yield	-0.37

Metric
Cash & Equivalents	74.56M
Accounts Receivable	2.59M
Inventory
Goodwill
Debt to Capitalization	0.22
Debt to Assets	0.06
Current Ratio	3.95
Quick Ratio	3.53

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.44
R&D to Revenue	2.07
SG&A to Revenue	0.59